Opens in a new tab or window Roughly half as many patients with cirrhosis in remission from overt hepatic encephalopathy (OHE) experienced a breakthrough episode with rifaximin monotherapy ...

For patients with a history of overt hepatic encephalopathy (OHE), rifaximin monotherapy (MT) results in significantly fewer OHE episodes than lactulose (LAC) MT, according to a study presented at ...

Rifaximin monotherapy reduces risk for breakthrough OHE episode and results in a lower mortality rate than lactulose monotherapy. HealthDay News — For patients with a history of overt hepatic ...

M ONDAY, Oct. 28, 2024 (HealthDay News) -- For patients with a history of overt hepatic encephalopathy (OHE), rifaximin ...

This post hoc analysis of data from two randomized trials evaluated the efficacy of Xifaxan monotherapy compared to lactulose monotherapy for risk reduction of overt hepatic encephalopathy (OHE ...

Rifaximin is a minimally absorbed antibiotic that is FDA-approved for treatment of travelers' diarrhea and prevention of hepatic encephalopathy. The primary endpoint (patient-reported "adequate ...

Get detailed information on Rifaximin, including pronunciation ... certain bacteria and liver disease affecting the brain (hepatic encephalopathy). It prevents the growth of bacteria inside ...